Expression of CCR4 by the malignant T cells in CTCL has been exploited for targeted therapy by the use of anti-CCR4 monoclonal antibody mogamulizumab. The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.